Lung Cancer Dispatch
Follow
Find tag "taxanes"
3.7K views | +0 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Rescooped by Cancer Commons from Melanoma Dispatch
Scoop.it!

First Treatment for Pain Caused by Chemotherapy

First Treatment for Pain Caused by Chemotherapy | Lung Cancer Dispatch | Scoop.it

Conventional chemotherapy can damage nerves, causing pain and numbness, particularly in the hands and feet. Called neuropathy, this side effect can last months or even years after the completion of chemotherapy and there are currently no effective treatments. A new JAMA study shows that chemotherapy-induced neuropathy can be lessened with a drug called duloxetine (Cymbalta), which has also been shown to alleviate neuropathy in people with diabetes. The new study included 231 people who reported pain of at least 4 (on a scale of 0 to 10) after treatment with oxaliplatin or taxanes such as paclitaxel. Nearly 60% of those treated with duloxetine reported pain relief and those who had been treated with oxaliplatin may have benefited the most.



Cancer Commons's insight:

Medical Express│Apr 2, 2013

more...
Cancer Commons's curator insight, April 2, 2013 7:43 PM

Medical Xpress│Apr 2, 2013

Cancer Commons's curator insight, April 3, 2013 11:23 AM

Medical Express│Apr 2, 2013

Suggested by Cancer Commons
Scoop.it!

Avastin-Taxol Regimen May Be Effective Late-Line Treatment for Advanced Non-Squamous NSCLC

Avastin-Taxol Regimen May Be Effective Late-Line Treatment for Advanced Non-Squamous NSCLC | Lung Cancer Dispatch | Scoop.it

A retrospective study assessed the use of weekly bevacizumab (Avastin) along with paclitaxel (Taxol) every 3 weeks in patients with advanced non-squamous, non-small cell lung cancer (NSCLC) who had previously received at least three rounds of treatment. The Avastin-Taxol combination was found to be an effective anti-tumor treatment. Some patients experienced serious side effects, including one death. However, overall toxicity was deemed acceptable compared to typical chemotherapy results in similar patients.

Cancer Commons's insight:

Lung Cancer | Feb 14, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

CHFR Protein Levels Predict Effectiveness of Chemotherapy

CHFR Protein Levels Predict Effectiveness of Chemotherapy | Lung Cancer Dispatch | Scoop.it

A study of patients with advanced non-small cell lung cancer (NSCLC) given chemotherapy with carboplatin (Paraplatin) and paclitaxel (Taxol or Abraxane) found that patients with lower levels of the protein CHFR were more likely to respond to the treatment and survived longer than patients with high CHFR levels. These findings suggest that CHFR levels could be a useful biomarker for indicating patients likely to respond to so-called taxane chemotherapy drugs like Taxol, Abraxane, or docetaxel (Taxotere). In the future, treatments that target CHFR may be developed to increase responsiveness to taxane chemotherapy in patients with high CHFR levels.

Cancer Commons's insight:

Clinical Cancer Research | Feb 5, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Abraxane-Paraplatin Combination May be Safe and Effective in Elderly Patients with Advanced Lung Cancer

A recent study examined first-line treatment with the chemotherapy agent carboplatin (Paraplatin) combined with either albumin-bound paclitaxel (Abraxane) or standard solvent-based paclitaxel (Taxol) in both elderly and younger patients with advanced non-small cell lung cancer (NSCLC). Patients treated with Abraxane/Paraplatin exhibited higher treatment response rates and fewer toxic side effects in both age groups, and elderly patients (age 70+ years) experienced longer periods without cancer progression and longer overall survival with Abraxane/Paraplatin compared to Taxol/Paraplatin treatment. Abraxane plus Paraplatin may constitute a safe, effective first-line treatment for elderly patients with advanced NSCLC, a group that has been traditionally undertreated.


Research paper: http://annonc.oxfordjournals.org/content/24/2/314.long

Cancer Commons's insight:

Annals of Oncology | Nov 2, 2012

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Trial Supports the Use of Pemetrexed for Chinese NSCLC Patients

Trial Supports the Use of Pemetrexed for Chinese NSCLC Patients | Lung Cancer Dispatch | Scoop.it

A recent study compared the drug docetaxel with pemetrexed in Chinese patients with advanced, non-squamous, non-small cell lung cancer (NSCLC). The results show that both treatments are similarly effective. Patients who took pemetrexed also experienced fewer adverse effects.

Cancer Commons's insight:

Lung Cancer | Nov 21, 2012

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

FDA Approves Abraxane for Treatment of Advanced NSCLC

FDA Approves Abraxane for Treatment of Advanced NSCLC | Lung Cancer Dispatch | Scoop.it

The FDA has approved the use of breast cancer drug Abraxane in conjunction with carboplatin for non-small cell lung cancer (NSCLC) treatment. Abraxane, manufactured by Celgene Corp., combines paclitaxel with a protein called albumin. Earlier this year, a large clinical trial found Abraxane plus carboplatin to be more effective in shrinking advanced NSCLC tumors than the standard paclitaxel drug Taxol plus carboplatin. Abraxane treatment may be particularly effective for patients with squamous NSCLC patients age 70 years or older and North American patients.

Cancer Commons's insight:

Huffington Post | Oct 12, 2012

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Taxotere-Afinitor Combination Only Modestly Effective in Advanced NSCLC

Taxotere-Afinitor Combination Only Modestly Effective in Advanced NSCLC | Lung Cancer Dispatch | Scoop.it

A phase II clinical trial examined the use of the chemotherapy drug docetaxel (Taxotere) combined with everolimus (Afinitor), a member of a family of drugs called mTOR inhibitors, as second- or third-line treatment in advanced non-small cell lung cancer (NSCLC). The treatment was well tolerated, but only modestly effective compared to standard therapy in similar patients. The patients in the study had not been selected for any specific biomarkers; better effectiveness may be achieved in patients with relevant biomarkers.

Cancer Commons's insight:

Journal of Thoracic Oncology | Feb 14, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Reolysin Shrinks Lung Cancer Tumors in Clinical Trial

A phase II study of the novel cancer treatment Reolysin in 20 patients with advanced squamous cell carcinoma (SCC) of the lung, a type of non-small cell lung cancer, showed a reduction in tumor size in 95% of patients. Patients were given Reolysin in combination with the chemotherapy drugs carboplatin (Paraplatin) and paclitaxel (Taxol or Abraxane); on average, their tumors shrank by about a third. This finding suggests that Reolysin may be useful for presurgical treatment of tumors. Reolysin, made by the company Oncolytics, is a form of a virus called reovirus. Most adults have been exposed to reovirus, which usually does not produce symptoms. However, reovirus selectively infects and kills tumor cells.


Press release: http://www.oncolyticsbiotech.com/news_items/details?press_release_id=1921

Cancer Commons's insight:

Reuters | Feb 8, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Conatumumab Does Not Appear to Benefit Patients with Advanced Lung Cancer

Conatumumab is an antibody (a type of immune system protein) that targets TR-2, a protein that is expressed in tumor tissue in a variety of cancer types. A phase II study of patients with previously untreated advanced non-small cell lung cancer (NSCLC) receiving either conatumumab or placebo in combination with standard paclitaxel (Taxol)-carboplatin (Paraplatin) chemotherapy showed that conatumumab was well tolerated, but did not improve clinical outcomes. However, it is possible that in patients selected for relevant biomarkers, conatumumab may show effectiveness that is not seen in an unselected patient population.

Cancer Commons's insight:

Journal of Thoracic Oncology | Jan 29, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

First Success for KRAS Targeted Treatment

A phase II clinical trial found that the addition of selumetinib to docetaxel improves treatment of KRAS-mutant non-small cell lung cancer (NSCLC). Mutated KRAS occurs in 20% of all NSCLC tumors and is more commonly reported in current and former smokers and white patients. This study marks the first time that a targeted KRAS treatment has proven successful in a clinical trial.

Cancer Commons's insight:

The Lancet Oncology | Jan 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Non-squamous NSCLC Study Results Disappoint Drug-Maker Eli Lilly

Non-squamous NSCLC Study Results Disappoint Drug-Maker Eli Lilly | Lung Cancer Dispatch | Scoop.it

Alimta manufacturer Eli Lilly had high hopes for the PointBreak study, which compared an Alimta-based, first-line, non-squamous, non-small cell lung cancer (NSCLC) treatment with a well-established, Taxol-based standard. Initial results were promising, but the 939 patient study ultimately did not show significantly improved patient survival for the Alimta regimen.

Cancer Commons's insight:

Ground Report | Nov 10, 2012

more...
No comment yet.